539997

Kwality Pharma share price & financials

Price
₹2,704
Market cap
₹3.8k Cr
Sector
Healthcare

What Kwality Pharma does

Kwality Pharmaceuticals is an Amritsar (Punjab)-headquartered manufacturer that develops and produces formulations across General, Beta-Lactam, Cephalosporins, Oncology and Biologics categories, spanning oral solids, injectables, dry syrups, ointments and sachets. It earns mainly as an out-licensing and contract-manufacturing (CDMO) partner, supplying finished formulations to clients across LatAm, MENA, Europe, Asia and Africa rather than selling under its own retail brand. The company runs six manufacturing units across two campuses (Amritsar and Himachal), most of which are EU-GMP approved, and is expanding into biologics (erythropoietin) and a new hormone-manufacturing unit. Market access depends on regulatory filings and accreditations such as EU-GMP, PIC/S, WHO GMP, ANVISA, INVIMA and SFDA that qualify it to supply regulated and semi-regulated export markets.

R&D scientists (DSIR-recognized)
80+
Manufacturing units
6 (Units 1-5 operational — General, Beta Lactam, Oncology, Cephalosporins, Biologics; Unit 6 Hormones under construction)
EU-GMP approved units
4 of 5 manufacturing units
Countries served
70+
Regulatory filings completed
600+ across multiple countries
Formulations in portfolio
1000+ across 25+ therapeutic areas
Founded 1983Headquarters Amritsar, Punjab, IndiaEmployees 1,700 (2025-12-31) Company website

Quarterly results

Q1 FY27: revenue up 45.9%, net profit up 116.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue90 84 116 111 111 +23%123 +46%157 +35%162 +46%
EBITDA20 18 26 24 25 +25%30 +67%39 +50%41 +71%
Net profit8 9 14 12 14 +75%16 +78%25 +79%26 +117%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +279.9% 1Y

₹1.0k₹2.0k₹3.0kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹967.35 on 10 Sept 2025 → ₹3,675. High ₹3,675 (11 Sept 2026), low ₹838.2 (11 Nov 2025).

Financials, as filed

Revenue grew 26.0% a year over 3 years, FY23 to FY26. Operating margin held at 23.5%.

Year endingFY23FY24FY25FY26
Revenue₹251 Cr₹307 Cr₹370 Cr₹502 Cr
Operating profit₹60 Cr₹67 Cr₹81 Cr₹118 Cr
Operating margin23.9%21.8%21.9%23.5%
Interest₹6 Cr₹10 Cr₹9 Cr₹11 Cr
Depreciation₹15 Cr₹20 Cr₹19 Cr₹20 Cr
Net profit₹20 Cr₹23 Cr₹39 Cr₹67 Cr
Net margin8.0%7.5%10.5%13.3%
Cash from operations₹41 Cr₹43 Cr₹53 Cr₹17 Cr
Free cash flow₹-4 Cr₹17 Cr₹28 Cr₹-29 Cr
ROCE19.0%16.0%18.0%24.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr
Reserves₹51 Cr₹171 Cr₹190 Cr₹214 Cr₹280 Cr₹321 Cr
Borrowings₹41 Cr₹54 Cr₹90 Cr₹98 Cr₹110 Cr₹130 Cr
Other liabilities₹64 Cr₹105 Cr₹70 Cr₹72 Cr₹77 Cr₹130 Cr
Total liabilities₹166 Cr₹341 Cr₹361 Cr₹394 Cr₹478 Cr₹592 Cr
Fixed assets₹57 Cr₹92 Cr₹120 Cr₹139 Cr₹144 Cr₹156 Cr
Capital work in progress₹3 Cr₹12 Cr₹14 Cr₹0 Cr₹0 Cr₹17 Cr
Investments₹5 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹102 Cr₹237 Cr₹226 Cr₹255 Cr₹334 Cr₹420 Cr
Total assets₹166 Cr₹341 Cr₹361 Cr₹394 Cr₹478 Cr₹592 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −3.41 pp while FIIs added +3.13 pp. The shareholder count grew 31% to 13,279.

Promoters
54.9%
FIIs
3.1%
DIIs
0.6%
Public
41.5%

Since Jun 2025

  • Public −3.41 pp
  • FIIs +3.13 pp
  • DIIs +0.23 pp

How it drifted, 12 quarters

Over this window the public fell from 45.2% to 41.5% — −3.8 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 54.8%, DIIs 0.0%, Public 45.2%.Dec '23: Promoters 54.8%, DIIs 0.0%, Public 45.2%.Mar '24: Promoters 54.8%, Public 45.2%.Jun '24: Promoters 54.8%, Public 45.2%.Sep '24: Promoters 54.8%, DIIs 0.0%, Public 45.1%.Dec '24: Promoters 54.8%, DIIs 0.0%, Public 45.1%.Mar '25: Promoters 54.8%, DIIs 0.3%, Public 44.9%.Jun '25: Promoters 54.8%, DIIs 0.3%, Public 44.9%.Sep '25: Promoters 54.8%, DIIs 0.3%, Public 44.8%.Dec '25: Promoters 54.8%, FIIs 0.5%, DIIs 0.3%, Public 44.3%.Mar '26: Promoters 54.9%, FIIs 2.8%, DIIs 0.4%, Public 42.0%.Jun '26: Promoters 54.9%, FIIs 3.1%, DIIs 0.6%, Public 41.5%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Kwality Pharma above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ramesh Arora 26.03%unchanged
Ajay Arora 13.60%unchanged
Aditya Arora 11.96%unchanged
Deepak Bansal 8.39%−0.85 pp
Manohar Devabhaktuni 4.98%unchanged
Ark Global Emerging Companies, Lp FPI fund2.11%unchanged
Kadayam Ramnathan Bharat 1.98%unchanged
Dheeraj Kumar Lohia 1.66%−0.20 pp
Jani Bhasha Shaik 1.45%unchanged
Anju Arora 1.31%unchanged
Onkar Singh 1.09%unchanged
Geeta Arora 1.07%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹3675, this stock must grow earnings at 28% every year for 7 years. Our analysis caps realistic growth at ~51%. At that growth it is worth ₹10413 — upside of 183%.

Growth the price implies
28.3% a year
for 7 years, fading to 4%
It has actually compounded at
49.6% a year
net profit, FY23–FY26 · EPS 50.7%
The gap
-0.2 pp
183% downside if it only repeats history
Price today ₹3,675 Value at the reference growth ₹10,413.18

Change the assumptions yourself →

Learn to analyse Kwality Pharma

Guides on how to read this kind of business and the numbers that matter.